The incidence of hepatocellular carcinoma (HCC) has been increasing over the past decades, but improvements in systemic and locoregional therapies is increasing survival. Current locoregional treatment options include ablation, transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and stereotactic body radiotherapy (SBRT). There is ongoing research regarding the combination of systemic and local therapies to maximize treatment effect as well as in new non-invasive, image-guided techniques such as histotripsy. There is also active research in optimizing the delivery of therapy to tumors via nanostructures and viral-vector-mediated gene therapies. In many cases, patients require a combination of therapies to achieve tumor control and prolong survival. This article provides an overview of the most common liver-directed therapies for HCC as well as insight into more recent advances in personalized medicine and emerging techniques.
肝细胞癌（HCC）的发病率在过去数十年间持续上升，但全身治疗与局部区域治疗的进步显著提高了患者生存率。目前局部区域治疗手段包括消融术、经动脉化疗栓塞术（TACE）、经动脉放射栓塞术（TARE）以及立体定向体部放疗（SBRT）。当前研究聚焦于全身治疗与局部治疗的联合应用以最大化疗效，同时探索新型无创影像引导技术（如组织粉碎术）。通过纳米结构递送系统和病毒载体介导的基因疗法优化肿瘤靶向治疗的研究也日益活跃。多数患者需采用联合治疗方案以实现肿瘤控制并延长生存期。本文系统综述HCC最常用的肝脏定向治疗方法，并深入探讨个体化医疗的最新进展及新兴技术。
New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma
肿瘤(癌症)患者之家